Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma.

Taşkaldıran I, Gökbulut P, Yiğit H, Önder ÇE

Acta diabetologica22 May 2026

PMID42171706 (opens in a new tab)DOI10.1007/s00592-026-02702-8 (opens in a new tab)PepBankPUB-42171706
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 55-year-old woman with obesity and prediabetes, fasting plasma glucose rose from 107 to 169 mg/dL and HbA1c from 6.0% to 6.6% after one month of semaglutide 0.25 mg.

    In plain wordsIn one woman with obesity and prediabetes, blood sugar measures rose after one month of low-dose semaglutide, and the authors do not claim a cause.

    Peptide
    Semaglutide
    Outcome
    IncreaseFasting plasma glucose and HbA1c after one month
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg once weekly · one monthAs given in this study (human).

    Measurements

    Fasting plasma glucose
    107 mg/dL
    baseline
    Fasting plasma glucose
    169 mg/dL
    after one month
    HbA1c
    6%
    baseline
    HbA1c
    6.6%
    after one month

    Source sentences

    Summary
    After one month, despite a 4 kg weight loss and no significant gastrointestinal symptoms, fasting plasma glucose increased to 169 mg/dL and glycated haemoglobin to 6.6%.
    2 context sentences
    Summary · context
    We report a 55-year old woman with obesity and prediabetes who started once-weekly semaglutide 0.25 mg for weight management and glycaemic control.
    Summary · context
    Baseline fasting plasma glucose was 107 mg/dL and glycated haemoglobin was 6.0%.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 55-year-old woman with obesity and prediabetes, body weight fell by 4 kg after one month of semaglutide.

    In plain wordsIn one woman with obesity and prediabetes, weight fell by 4 kg after one month of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight after one month
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg once weekly · one monthAs given in this study (human).

    Measurements

    Weight loss
    4 kg
    one month

    Source sentences

    Summary
    despite a 4 kg weight loss and no significant gastrointestinal symptoms, fasting plasma glucose increased to 169 mg/dL and glycated haemoglobin to 6.6%.
    2 context sentences
    Summary · context
    We report a 55-year old woman with obesity and prediabetes who started once-weekly semaglutide 0.25 mg for weight management and glycaemic control.
    Summary · context
    Baseline fasting plasma glucose was 107 mg/dL and glycated haemoglobin was 6.0%.
  3. 03HumanCase report or seriesSafety outcome

    In a 55-year-old woman with obesity and prediabetes, no significant gastrointestinal symptoms occurred in the first month of semaglutide.

    In plain wordsIn one woman starting semaglutide, no significant stomach or bowel symptoms occurred in the first month.

    Peptide
    Semaglutide
    Outcome
    No significant changeGastrointestinal symptoms
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.25 mg once weekly · one monthAs given in this study (human).

    Source sentences

    Summary
    and no significant gastrointestinal symptoms, fasting plasma glucose increased to 169 mg/dL and glycated haemoglobin to 6.6%.
    2 context sentences
    Summary · context
    We report a 55-year old woman with obesity and prediabetes who started once-weekly semaglutide 0.25 mg for weight management and glycaemic control.
    Summary · context
    Baseline fasting plasma glucose was 107 mg/dL and glycated haemoglobin was 6.0%.
  4. 04HumanCase report or seriesSafety outcome

    In a 55-year-old woman, a 4 x 3 cm pancreatic head mass with liver metastases was found after one month of semaglutide, and biopsy confirmed metastatic pancreatobiliary adenocarcinoma; the authors state no causality is implied.

    In plain wordsIn one woman, pancreatic cancer was found soon after starting semaglutide. The authors say this does not show semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    Not applicablePancreatic adenocarcinoma diagnosed after starting semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    0.25 mg once weekly · one monthAs given in this study (human).

    Source sentences

    Summary
    Further evaluation revealed markedly elevated carbohydrate antigen 19-9 and pancreatic magnetic resonance imaging demonstrated a 4 × 3 cm irregular mass in the pancreatic head.
    3 context sentences
    Summary · context
    Surgical exploration identified liver metastases, and biopsy confirmed metastatic pancreatobiliary adenocarcinoma.
    Summary · context
    We report a 55-year old woman with obesity and prediabetes who started once-weekly semaglutide 0.25 mg for weight management and glycaemic control.
    Summary · context
    Baseline fasting plasma glucose was 107 mg/dL and glycated haemoglobin was 6.0%.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.